Developer docs
API playgroundTry for free, no card

Search company profiles

Retmarker

Full company profile

uuid0028eat

Namestring
Retmarker
Legal namestring
Retmarker, SA
Websiteurl
retmarker.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Retmarker S.A. is a Coimbra, Portugal-based medical-device software company that builds AI-driven retinal image analysis tools to detect and monitor diabetic retinopathy (DR) and age-related macular degeneration (AMD). Its core technology applies computer vision to color fundus photographs to detect microaneurysms and other lesions; the proprietary co-registration algorithm licensed from Portuguese research institute AIBILI enables temporal comparison of retinal images to compute microaneurysm formation and disappearance rates, supporting prediction of sight-threatening DR complications. The product suite comprises three modules — Retmarker DR Screening (population-based screening, Class IIa certified in the EU and approved in Australia), Retmarker DR Biomarker (EMA-recognized for clinical-trial patient enrichment), and RetmarkerAMD Research (validated in Nature: Eye, 2019) — serving DR screening providers, clinical-trial sponsors, and AMD researchers.

The company sells primarily through B2B direct sales in Portugal (Retmarker S.A.) and via distribution partner Meteda s.r.l. in Italy and the broader EMEA region. Pricing is quote-based and not publicly disclosed; revenue streams consist of medical-device software licensing on a recurring basis plus professional services for implementing population-based screening programs. Retmarker was founded in December 2008 as a spin-out of Critical Software (originally Critical Health S.A.) and has been majority-owned by Italian diabetes-software provider Meteda since 2021. With a reported headcount of 1–10 employees and no disclosed venture funding, Retmarker operates as a small, specialized clinical-AI vendor whose commercial scale is closely tied to Meteda's EMEA distribution reach.

Short descriptiontext

Retmarker S.A. is a Coimbra, Portugal-based medical-device software company that applies AI-driven computer vision to retinal fundus images for diabetic retinopathy screening, DR complication risk prediction (via microaneurysm turnover), and AMD lesion annotation, serving screening providers, clinical-trial sponsors, and researchers across EMEA.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCoimbra, Portugal
HQ citystring
Coimbra
HQ countrystring
Portugal
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
diabetic retinopathy screening, retinal image analysis, AI medical devices, ophthalmic diagnostics, fundus photography AI
Industry3 codes
PRIMARYHLAFAKAI
Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging)
SECONDARYHLAKAKAN
Ocular Imaging & Diagnostic Testing Centers
SECONDARYHLACAOAM
Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
NAICS code3 codes
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
  • Services-Commercial Physical & Biological Research8731
Product category
Ophthalmic Diagnostic Software
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Software Licenses
TypeSubscription Recurring
Description

Sale/licensing of Class IIa certified medical device software for Diabetic Retinopathy screening, biomarker analysis, and AMD research. Products include DR Screening, DR Biomarker, and AMD Research modules.

retmarker.com
2Professional Services
TypeProfessional Services
Description

Professional services in implementation of efficient and effective population-based screening services for DR providers.

retmarker.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1Retmarker Screening
Description

Highly reliable and affordable Diabetic Retinopathy Screening technology, certified as class IIa medical device in Europe and approved in Australia.

retmarker.com
+2 more records
Core offering1 text field

Retmarker develops AI-powered medical device software that analyzes retinal fundus photographs to automate diabetic retinopathy (DR) screening and AMD research workflows. Its three commercial offerings — DR Screening (population-based screening), DR Biomarker (longitudinal microaneurysm turnover analytics for predicting sight-threatening complications), and AMD Research (sem-automated lesion annotation) — are sold or licensed to DR screening providers, clinical-trial sponsors, and academic researchers. Technology is certified as a Class IIa medical device in Europe and approved in Australia.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Less than 10% of diabetics need referral - AI helps identify them efficiently
Product overview1 text field

Retmarker provides a suite of automated AI-powered medical devices for retinal disease analysis and vision loss prevention. The product portfolio consists of three integrated tools: Retmarker DR Screening (for population-based diabetic retinopathy screening using fundus photography), Retmarker DR Biomarker (for predicting DR complications through microaneurysm turnover analysis in clinical trials), and Retmarker AMD Research (for semiautomated grading and annotation of AMD lesions in epidemiological studies). All products leverage proprietary computer vision algorithms to analyze retinal images, with DR Screening and DR Biomarker certified as class IIa medical devices in Europe. The technology originated from Critical Software and is now part of METEDA (Italian diabetes software provider).

Product and service3 records
1Retmarker DR Screening
CategoryAI Medical Device Software / DR Screening
Description

Automated AI-powered diabetic retinopathy screening technology that analyzes retinal fundus images to identify patients requiring referral to a specialist. Certified as Class IIa medical device in Europe and approved in Australia. Aimed at DR screening providers running population-based screening programs.

2Retmarker DR Biomarker
CategoryAI Medical Device Software / Predictive Biomarker
Description

Predicts diabetic retinopathy sight-threatening complications by analyzing multiple retinal images taken over time and computing microaneurysm formation and disappearance rates. Used in clinical trials and research for risk stratification and patient enrollment. Validated as a Class IIa medical device in Europe.

3Retmarker AMD Research
CategoryAI Medical Device Software / AMD Research
Description

Semiautomatic grading software for Age-Related Macular Degeneration that provides simplified analysis and annotation of AMD lesions in retinal images, including Drusen (with confluence), Hypopigmentation, Hyperpigmentation, Geographic Atrophy and Exudative Lesions, plus multimodal comparison of annotations. Validated and published in Nature: Eye (2019). Intended for AMD epidemiological and clinical studies.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-01-01
Description

During 2021, METEDA s.r.l. bought a majority stake in Retmarker company. METEDA is an Italian provider of innovative and technologically advanced software and hardware solutions for diabetes and nutrition, operating throughout the EMEA Region and serving more than 90% of diabetes centers in Italy.

2AIBILI
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership with Portuguese research institute AIBILI (European Vision Institute Clinical Research Network coordinating centre). Founded and led by Professor José Cunha-Vaz, a distinguished doctor scientist specializing in retina and diabetic retinopathy research. Through the partnership, Retmarker gained access to a license of a proprietary and patented co-registration algorithm.

retmarker.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Retmarker was founded as a spin-out from Critical Software (now Critical Group) in December 2008, originally called Critical Health S.A.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Independent study led by A. Tufail from Moorfields Eye Hospital evaluated Retmarker technology in real life conditions, finding best specificity among evaluated technologies.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Heidelberg Engineering produces advanced diagnostic imaging devices for ophthalmology (e.g., Spectralis OCT). Its retinal imaging solutions are used in the same DR screening clinical workflows where Retmarker's AI is applied.

TypeEmerging player
Description

Thirona specializes in AI-based medical image analysis including retinal image analysis (RetCAD). It competes with Retmarker in AI retinal screening and diagnostic imaging, with overlap in European markets.

TypeBroad incumbent
Description

Optos (a Nikon company) produces ultra-widefield retinal imaging devices used in DR screening and ophthalmology. While not an AI software competitor, it operates broadly in the retinal imaging ecosystem where Retmarker is deployed.

TypeDirect peer
Description

Eyenuk develops EyeArt, a widely deployed FDA-cleared AI system for autonomous diabetic retinopathy screening. It is the closest direct competitor to Retmarker's DR Screening product, serving similar screening programs with a similar computer-vision approach.

TypeBroad incumbent
Description

Topcon Healthcare provides ophthalmic imaging and screening solutions including fundus cameras and AI-enabled screening workflows. Its screening ecosystem overlaps with Retmarker's positioning in primary-care DR screening.

6Carl Zeiss Meditec
TypeBroad incumbent
Description

Carl Zeiss Meditec is a major ophthalmic medical device incumbent with products spanning imaging, diagnostics, and surgical systems. Its retinal imaging devices overlap with the workflow in which Retmarker AI software operates.

TypeEmerging player
Description

Voxeleron provides AI-based ophthalmic image analysis software focused on retinal imaging research workflows. It overlaps with Retmarker's AMD Research product line in serving research and clinical study use cases for retinal lesion analysis.

TypeDirect peer
Description

Digital Diagnostics developed IDx-DR, the first FDA-cleared autonomous AI for diabetic retinopathy detection. It directly competes with Retmarker in AI-based DR screening for primary care and screening programs.

TypeDirect peer
Description

AEYE Health builds AI-based retinal diagnostics for DR screening with FDA clearance. It is a direct peer offering similar AI screening solutions for diabetic retinopathy, targeting similar point-of-care and screening workflows.

TypeDirect peer
Description

Ikerian (formerly RetinAI Medical) develops AI platforms for ophthalmic image analysis covering DR, AMD, and other retinal diseases, closely aligned with Retmarker's AMD Research and DR Screening products.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Retmarker

Ophthalmic Diagnostic Softwareretmarker.com

Retmarker S.A. is a Coimbra, Portugal-based medical-device software company that applies AI-driven computer vision to retinal fundus images for diabetic retinopathy screening, DR complication risk prediction (via microaneurysm turnover), and AMD lesion annotation, serving screening providers, clinical-trial sponsors, and researchers across EMEA.

What Retmarker does

Retmarker S.A. is a Coimbra, Portugal-based medical-device software company that builds AI-driven retinal image analysis tools to detect and monitor diabetic retinopathy (DR) and age-related macular degeneration (AMD). Its core technology applies computer vision to color fundus photographs to detect microaneurysms and other lesions; the proprietary co-registration algorithm licensed from Portuguese research institute AIBILI enables temporal comparison of retinal images to compute microaneurysm formation and disappearance rates, supporting prediction of sight-threatening DR complications. The product suite comprises three modules — Retmarker DR Screening (population-based screening, Class IIa certified in the EU and approved in Australia), Retmarker DR Biomarker (EMA-recognized for clinical-trial patient enrichment), and RetmarkerAMD Research (validated in Nature: Eye, 2019) — serving DR screening providers, clinical-trial sponsors, and AMD researchers.

The company sells primarily through B2B direct sales in Portugal (Retmarker S.A.) and via distribution partner Meteda s.r.l. in Italy and the broader EMEA region. Pricing is quote-based and not publicly disclosed; revenue streams consist of medical-device software licensing on a recurring basis plus professional services for implementing population-based screening programs. Retmarker was founded in December 2008 as a spin-out of Critical Software (originally Critical Health S.A.) and has been majority-owned by Italian diabetes-software provider Meteda since 2021. With a reported headcount of 1–10 employees and no disclosed venture funding, Retmarker operates as a small, specialized clinical-AI vendor whose commercial scale is closely tied to Meteda's EMEA distribution reach.

Retmarker firmographics

Firmographics
Name
Retmarker
Legal name
Retmarker, SA
Website
https://retmarker.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
1–10 employees
Short description
Retmarker S.A. is a Coimbra, Portugal-based medical-device software company that applies AI-driven computer vision to retinal fundus images for diabetic retinopathy screening, DR complication risk prediction (via microaneurysm turnover), and AMD lesion annotation, serving screening providers, clinical-trial sponsors, and researchers across EMEA.
Ownership category
akta.pro rank

Retmarker industry classification

Industry
Product category
Ophthalmic Diagnostic Software
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAFAKAI
Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging)
SECONDARYHLAKAKAN
Ocular Imaging & Diagnostic Testing Centers
SECONDARYHLACAOAM
Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)

Keywords

  • Diabetic retinopathy screening
  • Retinal image analysis
  • AI medical devices
  • Ophthalmic diagnostics
  • Fundus photography AI

Where Retmarker is headquartered

Location

Headquarters

HQ city
Coimbra
HQ country
Portugal
HQ region
Europe

Offices2 records

Markets served

Retmarker business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Medical Device Software Licenses: Sale/licensing of Class IIa certified medical device software for Diabetic Retinopathy screening, biomarker analysis, and AMD research. Products include DR Screening, DR Biomarker, and AMD Research modules.
  2. Professional Services: Professional services in implementation of efficient and effective population-based screening services for DR providers.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Retmarker product offering

Product offering

Core offering

Retmarker develops AI-powered medical device software that analyzes retinal fundus photographs to automate diabetic retinopathy (DR) screening and AMD research workflows. Its three commercial offerings — DR Screening (population-based screening), DR Biomarker (longitudinal microaneurysm turnover analytics for predicting sight-threatening complications), and AMD Research (sem-automated lesion annotation) — are sold or licensed to DR screening providers, clinical-trial sponsors, and academic researchers. Technology is certified as a Class IIa medical device in Europe and approved in Australia.

Product overview

Retmarker provides a suite of automated AI-powered medical devices for retinal disease analysis and vision loss prevention. The product portfolio consists of three integrated tools: Retmarker DR Screening (for population-based diabetic retinopathy screening using fundus photography), Retmarker DR Biomarker (for predicting DR complications through microaneurysm turnover analysis in clinical trials), and Retmarker AMD Research (for semiautomated grading and annotation of AMD lesions in epidemiological studies). All products leverage proprietary computer vision algorithms to analyze retinal images, with DR Screening and DR Biomarker certified as class IIa medical devices in Europe. The technology originated from Critical Software and is now part of METEDA (Italian diabetes software provider).

Differentiator

Problem solved

Functional benefit

Brands

  • Retmarker Screening: Highly reliable and affordable Diabetic Retinopathy Screening technology, certified as class IIa medical device in Europe and approved in Australia.
  • Retmarker DR Biomarker
  • RetmarkerAMD Research

Products and services

  • Retmarker DR Screening Automated AI-powered diabetic retinopathy screening technology that analyzes retinal fundus images to identify patients requiring referral to a specialist. Certified as Class IIa medical device in Europe and approved in Australia. Aimed at DR screening providers running population-based screening programs.
  • Retmarker DR Biomarker Predicts diabetic retinopathy sight-threatening complications by analyzing multiple retinal images taken over time and computing microaneurysm formation and disappearance rates. Used in clinical trials and research for risk stratification and patient enrollment. Validated as a Class IIa medical device in Europe.
  • Retmarker AMD Research Semiautomatic grading software for Age-Related Macular Degeneration that provides simplified analysis and annotation of AMD lesions in retinal images, including Drusen (with confluence), Hypopigmentation, Hyperpigmentation, Geographic Atrophy and Exudative Lesions, plus multimodal comparison of annotations. Validated and published in Nature: Eye (2019). Intended for AMD epidemiological and clinical studies.

Quantifiable outcome

  • Less than 10% of diabetics need referral - AI helps identify them efficiently

Companies that use Retmarker

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Retmarker technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Retmarker partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • METEDAcoreChannel Partner/ Reseller/ Distributor · 1 January 2021During 2021, METEDA s.r.l. bought a majority stake in Retmarker company. METEDA is an Italian provider of innovative and technologically advanced software and hardware solutions for diabetes and nutrition, operating throughout the EMEA Region and serving more than 90% of diabetes centers in Italy.
  • AIBILIcoreStrategic or Co-development PartnerStrategic partnership with Portuguese research institute AIBILI (European Vision Institute Clinical Research Network coordinating centre). Founded and led by Professor José Cunha-Vaz, a distinguished doctor scientist specializing in retina and diabetic retinopathy research. Through the partnership, Retmarker gained access to a license of a proprietary and patented co-registration algorithm.
  • Critical Software / Critical GroupminorStrategic or Co-development PartnerRetmarker was founded as a spin-out from Critical Software (now Critical Group) in December 2008, originally called Critical Health S.A.
  • Moorfields Eye HospitalminorStrategic or Co-development PartnerIndependent study led by A. Tufail from Moorfields Eye Hospital evaluated Retmarker technology in real life conditions, finding best specificity among evaluated technologies.

Scale indicators5 records

Recent moves7 records

Expansion highlights4 records

Retmarker competitors and assessment

Company assessment

Broad incumbents

  • Heidelberg Engineering: Heidelberg Engineering produces advanced diagnostic imaging devices for ophthalmology (e.g., Spectralis OCT). Its retinal imaging solutions are used in the same DR screening clinical workflows where Retmarker's AI is applied.
  • Optos: Optos (a Nikon company) produces ultra-widefield retinal imaging devices used in DR screening and ophthalmology. While not an AI software competitor, it operates broadly in the retinal imaging ecosystem where Retmarker is deployed.
  • Topcon Healthcare: Topcon Healthcare provides ophthalmic imaging and screening solutions including fundus cameras and AI-enabled screening workflows. Its screening ecosystem overlaps with Retmarker's positioning in primary-care DR screening.
  • Carl Zeiss Meditec: Carl Zeiss Meditec is a major ophthalmic medical device incumbent with products spanning imaging, diagnostics, and surgical systems. Its retinal imaging devices overlap with the workflow in which Retmarker AI software operates.

Emerging players

  • Thirona: Thirona specializes in AI-based medical image analysis including retinal image analysis (RetCAD). It competes with Retmarker in AI retinal screening and diagnostic imaging, with overlap in European markets.
  • Voxeleron: Voxeleron provides AI-based ophthalmic image analysis software focused on retinal imaging research workflows. It overlaps with Retmarker's AMD Research product line in serving research and clinical study use cases for retinal lesion analysis.

Direct peers

  • Eyenuk: Eyenuk develops EyeArt, a widely deployed FDA-cleared AI system for autonomous diabetic retinopathy screening. It is the closest direct competitor to Retmarker's DR Screening product, serving similar screening programs with a similar computer-vision approach.
  • Digital Diagnostics: Digital Diagnostics developed IDx-DR, the first FDA-cleared autonomous AI for diabetic retinopathy detection. It directly competes with Retmarker in AI-based DR screening for primary care and screening programs.
  • AEYE Health: AEYE Health builds AI-based retinal diagnostics for DR screening with FDA clearance. It is a direct peer offering similar AI screening solutions for diabetic retinopathy, targeting similar point-of-care and screening workflows.
  • Ikerian (RetinAI Medical): Ikerian (formerly RetinAI Medical) develops AI platforms for ophthalmic image analysis covering DR, AMD, and other retinal diseases, closely aligned with Retmarker's AMD Research and DR Screening products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Retmarker social profiles

Digital presence

Retmarker compliance and trust

Trust signal

Compliance2 records

Retmarker financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Retmarker leadership team

Management profile

Number of profiles

Profiles3 records

Retmarker funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Retmarker M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Retmarker

What does Retmarker do?

Retmarker develops AI-powered medical device software that analyzes retinal fundus photographs to automate diabetic retinopathy (DR) screening and AMD research workflows. Its three commercial offerings — DR Screening (population-based screening), DR Biomarker (longitudinal microaneurysm turnover analytics for predicting sight-threatening complications), and AMD Research (sem-automated lesion annotation) — are sold or licensed to DR screening providers, clinical-trial sponsors, and academic researchers. Technology is certified as a Class IIa medical device in Europe and approved in Australia.

Is Retmarker a public or private company?

Retmarker is a private company. It is classified as corporate owned and is currently operating.

When was Retmarker founded?

Retmarker was founded in 2008. It employs 1 to 10 people.

Where is Retmarker based?

Retmarker is headquartered in Coimbra, Portugal, in the Europe region.

How does Retmarker make money?

Two revenue lines are on record. Medical Device Software Licenses are the primary driver. The others are professional Services.

Who are Retmarker's main competitors?

Broad incumbents on record are Heidelberg Engineering, Optos, Topcon Healthcare and Carl Zeiss Meditec. Emerging players are Thirona and Voxeleron. Direct peers are Eyenuk, Digital Diagnostics, AEYE Health and Ikerian (RetinAI Medical).

Does Retmarker have an API?

No public API is recorded for Retmarker.

What industry is Retmarker in?

Retmarker's product category is Ophthalmic Diagnostic Software. Its primary akta.pro industry code is HLAFAKAI, Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging), with a secondary code of HLAKAKAN, Ocular Imaging & Diagnostic Testing Centers. Its NAICS code is 54171 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals